Cortalix is a biotechnology company specializing in the development of nutraceuticals, diagnostics, radiopharmaceuticals, and immunotherapeutics. Our proprietary single-domain antibody (sdAb) discovery platform, also known as a nanobody platform, utilizes synthetic sdAb libraries to target novel biomarkers.
"Cortalix is a Dutch biotechnology company focused on the discovery and engineering of single-domain antibodies (VHH, nanobodies) for therapeutic, diagnostic, and analytical applications. Our integrated platform combines proprietary synthetic libraries with immune libraries generated through llama immunization, allowing us to identify high-affinity binders for a wide range of targets, including those considered difficult or intractable.We develop nanobodies for diverse applications, including radiopharmaceuticals (e.g. immuno-PET imaging and targeted radiotherapy), CAR-T cell therapy (nanobody-based targeting domains), and advanced diagnostics such as ELISA, bioanalysis, and affinity capture.
A particular strength of our platform is the ability to design and produce bi- and trispecific nanobodies. These multispecific constructs enhance cell-type specificity, especially relevant in oncology, and offer powerful means to modulate pharmacokinetics or create theranostic agents with both targeting and effector functions.
Cortalix provides end-to-end nanobody services, from discovery and optimization to production, conjugation and functionalization. We collaborate with industry and academic partners to deliver customized solutions, enabling the next generation of precision medicines and high-performance analytical tools.”
Website: www.cortalix.com
